Breaking News Instant updates and real-time market news.

TARO

Taro Pharmaceutical

$111.00

0.49 (0.44%)

, NVS

Novartis

$79.00

0.04 (0.05%)

17:08
10/03/16
10/03
17:08
10/03/16
17:08

Taro names Mariano Balaguer CFO, chief accounting officer

Taro Pharmaceutical Industries (TARO) announced the appointment of Mariano Balaguer as vice president, CFO and chief accounting officer, effective today. Balaguer has nearly 20 years of senior management experience in finance with global companies such as Novartis Consumer Health (NVS), Nestle (NSRGY) and most recently, the Global Strategic Portfolio Division of Henry Schein (HSIC).

TARO

Taro Pharmaceutical

$111.00

0.49 (0.44%)

NVS

Novartis

$79.00

0.04 (0.05%)

NSRGY

Nestle

$78.92

-0.1 (-0.13%)

HSIC

Henry Schein

$161.43

-1.55 (-0.95%)

  • 07

    Oct

  • 06

    Nov

TARO Taro Pharmaceutical
$111.00

0.49 (0.44%)

NVS Novartis
$79.00

0.04 (0.05%)

09/20/16
CHDN
09/20/16
INITIATION
Target $95
CHDN
Buy
Novartis initiated with a Buy at Chardan
Chardan initiated Novartis with a Buy and a $95 price target.
09/02/16
LEER
09/02/16
NO CHANGE
LEER
Outperform
Teva third Copaxone patent invalidated as expected, says Leerink
Leerink analyst Jason Gerberry says Teva (TEVA) suffered a largely expected loss in its Copaxone 40mg patent battle, with the Patent Trial and Appeal Board, or PTAB, ruling a third patent invalid. The analyst believes the company will likely appeal the loss, along with PTAB rulings rendered last week that other Copaxone patents were invalid. Gerberry sees the bull case scenario of Teva securing patent exclusivity of the Copaxone 40mg as unlikely and says a settlement with Momenta (MNTA) and Novartis (NVS) is the most logical course of action to mitigate 2017-2018E EPS risk. He reiterates an Outperform rating on Teva's shares.
08/31/16
PIPR
08/31/16
NO CHANGE
PIPR
Piper's Schimmer unsure of impact from Novartis CAR-T shakeup
Piper Jaffray analyst Joshua Schimmer said he's struggling with the implications of the news that Novartis (NVS) is reportedly eliminating its Cell and Gene Therapy unit as a stand-alone entity, which is primarily focused on development of CAR-T and adoptive immunotherapies. On the one hand, removing a leading competitor is a positive for the rest of the field, Schimmer tells investors in a research note. On the other hand, the move by Novartis could signal "significant challenges" in the field, the analyst adds. Schimmer continues to prefer companies "with unique and differentiated approaches," namely Bellicum Pharmaceuticals (BLCM), Cellectis (CLLS), Lion Biotechnologies (LBIO), Amgen (AMGN), Celgene (CELG) and bluebird bio (BLUE). Juno Therapeutics (JUNO) and Kite Pharma (KITE) are down 6% and 5%, respectively, in midday trading.
08/31/16
LEER
08/31/16
NO CHANGE
Target $61
LEER
Outperform
Teva price target lowered to $61 from $66 at Leerink
Leerink analyst Jason Gerberry lowered his price target for Teva (TEVA) to $61 from $66 on loss of Copaxone patent challenge as an upside catalyst. The analyst believes Teva's share price implies a generic entrant sometime in the second half of 2017 after losing an Inter Partes Review decision on two Copaxone 40mg anchor patents. In order to mitigate EPS downside in 2017-2018 and eliminate business uncertainty, Gerberry thinks the company should settle its Copaxone patent dispute with Novartis (NVS) and Momenta (MNTA), which he sees as "the most credible" generic threat. The analyst reiterates an Outperform rating on Teva's shares.
NSRGY Nestle
$78.92

-0.1 (-0.13%)

08/11/16
08/11/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Shake Shack (SHAK) upgraded to Buy from Neutral at SunTrust with analyst Jake Bartlett saying improved unit growth and its second quarter same-store sales miss creates a buying opportunity. 2. SeaWorld (SEAS) upgraded to Neutral from Underperform at Credit Suisse with analyst Benjamin Chalken citing recently lowered guidance, reset expectations, and balanced risk reward. 3. Cabot Oil & Gas (COG) upgraded to Outperform at Scotia Howard Weil with analyst Holly Stewart saying she expects infrastructure concerns will be reconciled by early 2018 with the inservice of 850 MMcf/d of contracted capacity and another 690 MMcf/d by early 2019. 4. American Eagle (AEO) upgraded to Buy from Hold at Wunderlich with analyst Eric Beder saying the company's momentum is "too strong" not to own the shares. 5. Nestle (NSRGY) upgraded to Buy from Hold at Societe Generale. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/11/16
SOCG
08/11/16
UPGRADE
SOCG
Buy
Nestle upgraded to Buy from Hold at Societe Generale
09/09/16
DBAB
09/09/16
UPGRADE
DBAB
Buy
Nestle upgraded to Buy from Hold at Deutsche Bank
09/13/16
GSCO
09/13/16
UPGRADE
GSCO
Buy
Nestle upgraded to Buy from Neutral at Goldman
HSIC Henry Schein
$161.43

-1.55 (-0.95%)

08/02/16
CLVD
08/02/16
NO CHANGE
CLVD
Henry Schein dental momentum continued through Q2, says Cleveland Research
Cleveland Research analyst Rob Eich channel work indicates Henry Schein's US dental momentum continued in Q2 with strong growth in both consumables and equipment. The analyst is modeling Q2 earnings of $1.64, versus consensus of $1.63 and reiterates his Buy rating.
03/16/16
FBCO
03/16/16
INITIATION
Target $170
FBCO
Neutral
Henry Schein initiated with a Neutral at Credit Suisse
Target $170.
09/12/16
BOFA
09/12/16
INITIATION
Target $185
BOFA
Buy
Henry Schein reinitiated with a Buy at BofA/Merrill
BofA/Merrill analyst Steven Valiquette reinstated coverage on Henry Schein with a Buy and $185 price target. The analyst expects growth to accelerate in 2H 2016 and recommends taking advantage of recent share weakness.
03/01/16
BRRR
03/01/16
UPGRADE
BRRR
Outperform
Henry Schein upgraded to Outperform from Market Perform at Barrington

TODAY'S FREE FLY STORIES

AZRX

AzurRx BioPharma

$3.51

-0.04 (-1.13%)

15:54
04/28/17
04/28
15:54
04/28/17
15:54
Hot Stocks
Breaking Hot Stocks news story on AzurRx BioPharma »

Matthew Balk reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OMF

OneMain Holdings

$23.36

-1.26 (-5.12%)

15:51
04/28/17
04/28
15:51
04/28/17
15:51
Options
Opening action in OneMain Holdings puts as shares drop »

Opening action in OneMain…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

  • 25

    May

CHFC

Chemical Financial

$47.97

-0.79 (-1.62%)

15:50
04/28/17
04/28
15:50
04/28/17
15:50
Upgrade
Chemical Financial rating change  »

Chemical Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

BOFI

BofI Holding

$24.76

0.52 (2.15%)

15:46
04/28/17
04/28
15:46
04/28/17
15:46
Options
BofI Holding call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 30

    May

B

Barnes Group

$55.35

2.1 (3.94%)

15:43
04/28/17
04/28
15:43
04/28/17
15:43
Downgrade
Barnes Group rating change  »

Barnes Group downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 09

    May

ADI

Analog Devices

$77.85

-0.13 (-0.17%)

15:36
04/28/17
04/28
15:36
04/28/17
15:36
Options
Analog Devices put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

MDXG

MiMedx

$11.40

0.3 (2.70%)

15:32
04/28/17
04/28
15:32
04/28/17
15:32
Recommendations
MiMedx analyst commentary  »

MiMedx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 30

    May

  • 06

    Jun

GST

Gastar Exploration

$1.31

0.01 (0.77%)

15:30
04/28/17
04/28
15:30
04/28/17
15:30
Conference/Events
Gastar Exploration to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 05

    May

CLVS

Clovis

$58.21

-0.43 (-0.73%)

15:26
04/28/17
04/28
15:26
04/28/17
15:26
Options
Clovis call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

$NSD

NASDAQ Market Internals

15:17
04/28/17
04/28
15:17
04/28/17
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FIG

Fortress

$8.04

0.005 (0.06%)

, SFTBF

SoftBank

$75.60

0.71 (0.95%)

15:17
04/28/17
04/28
15:17
04/28/17
15:17
Periodicals
Fortress exploring sale of Logan Circle bond fund unit, Reuters says »

Fortress Investment Group…

FIG

Fortress

$8.04

0.005 (0.06%)

SFTBF

SoftBank

$75.60

0.71 (0.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:16
04/28/17
04/28
15:16
04/28/17
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:15
04/28/17
04/28
15:15
04/28/17
15:15
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

CAG

Conagra Brands

$38.82

0.005 (0.01%)

15:11
04/28/17
04/28
15:11
04/28/17
15:11
Options
Downside put buyer in Conagra Foods »

Downside put buyer in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAH

Cardinal Health

$72.36

-0.78 (-1.07%)

15:10
04/28/17
04/28
15:10
04/28/17
15:10
Initiation
Cardinal Health initiated  »

Cardinal Health initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

FIG

Fortress

$8.04

0.01 (0.12%)

15:04
04/28/17
04/28
15:04
04/28/17
15:04
Periodicals
Breaking Periodicals news story on Fortress »

Fortress exploring sale…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

S

Sprint

$9.06

0.03 (0.33%)

15:01
04/28/17
04/28
15:01
04/28/17
15:01
Options
Sprint calls active ahead of earnings next week »

Sprint calls active ahead…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

GME

GameStop

$22.80

-0.3 (-1.30%)

14:56
04/28/17
04/28
14:56
04/28/17
14:56
Options
GameStop put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

  • 31

    May

BSX

Boston Scientific

$26.43

0.25 (0.95%)

14:55
04/28/17
04/28
14:55
04/28/17
14:55
Recommendations
Boston Scientific analyst commentary  »

Boston Scientific price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 07

    Jun

  • 27

    Jun

TKPYY

Takeda Pharmaceutical Co. Ltd.

$23.98

0.05 (0.21%)

14:51
04/28/17
04/28
14:51
04/28/17
14:51
Hot Stocks
FDA grants accelerated approval to Takeda's brigatinib »

On April 28, 2017, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PGR

Progressive

$39.76

-0.34 (-0.85%)

14:48
04/28/17
04/28
14:48
04/28/17
14:48
Conference/Events
The Progressive Corporation to hold a conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVO

Cenveo

$4.39

0.095 (2.21%)

14:48
04/28/17
04/28
14:48
04/28/17
14:48
Hot Stocks
Breaking Hot Stocks news story on Cenveo »

Nathu Ram Puri reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

BMY

Bristol-Myers

$56.01

0.34 (0.61%)

14:42
04/28/17
04/28
14:42
04/28/17
14:42
Hot Stocks
Bristol-Myers announces European Commission approval of Opdivo »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 03

    May

  • 06

    Jun

TAP

Molson Coors

$95.84

0.06 (0.06%)

14:41
04/28/17
04/28
14:41
04/28/17
14:41
Conference/Events
Molson Coors to hold an earnings follow-up conference call »

Management holds an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

IWM

iShares Trust Russell 2000 Index Fund

$139.37

-1.58 (-1.12%)

, RUT

Russell 2000 Index

14:40
04/28/17
04/28
14:40
04/28/17
14:40
Technical Analysis
On The Fly: Weekly technical notes for Russell 2000 »

The Russell 2000 (RUT)…

IWM

iShares Trust Russell 2000 Index Fund

$139.37

-1.58 (-1.12%)

RUT

Russell 2000 Index

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.